IL302887A - Prevention and treatment of angioedema - Google Patents
Prevention and treatment of angioedemaInfo
- Publication number
- IL302887A IL302887A IL302887A IL30288723A IL302887A IL 302887 A IL302887 A IL 302887A IL 302887 A IL302887 A IL 302887A IL 30288723 A IL30288723 A IL 30288723A IL 302887 A IL302887 A IL 302887A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- acceptable salt
- angioedema
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207273 | 2020-11-12 | ||
| PCT/EP2021/081493 WO2022101395A1 (en) | 2020-11-12 | 2021-11-12 | Prophylaxis and treatment of angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302887A true IL302887A (en) | 2023-07-01 |
Family
ID=73401436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302887A IL302887A (en) | 2020-11-12 | 2021-11-12 | Prevention and treatment of angioedema |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230338358A1 (https=) |
| EP (1) | EP4243824B1 (https=) |
| JP (1) | JP2023549849A (https=) |
| KR (1) | KR20230107269A (https=) |
| CN (1) | CN116685353A (https=) |
| AU (1) | AU2021376885A1 (https=) |
| CA (1) | CA3198246A1 (https=) |
| ES (1) | ES3061585T3 (https=) |
| IL (1) | IL302887A (https=) |
| MX (1) | MX2023005563A (https=) |
| WO (1) | WO2022101395A1 (https=) |
| ZA (1) | ZA202305122B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3062067T3 (en) * | 2022-03-25 | 2026-04-08 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
| TW202345810A (zh) * | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| WO2025037920A1 (ko) | 2023-08-16 | 2025-02-20 | 주식회사 엘지화학 | 수지 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005053660A2 (en) * | 2003-12-03 | 2005-06-16 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising danazol |
| US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| AR113839A1 (es) * | 2017-11-24 | 2020-06-17 | Pharvaris B V | Antagonistas del receptor b2 de bradiquinina |
-
2021
- 2021-11-12 CN CN202180080857.7A patent/CN116685353A/zh active Pending
- 2021-11-12 IL IL302887A patent/IL302887A/en unknown
- 2021-11-12 MX MX2023005563A patent/MX2023005563A/es unknown
- 2021-11-12 KR KR1020237018410A patent/KR20230107269A/ko active Pending
- 2021-11-12 JP JP2023528620A patent/JP2023549849A/ja active Pending
- 2021-11-12 ES ES21805547T patent/ES3061585T3/es active Active
- 2021-11-12 AU AU2021376885A patent/AU2021376885A1/en active Pending
- 2021-11-12 WO PCT/EP2021/081493 patent/WO2022101395A1/en not_active Ceased
- 2021-11-12 EP EP21805547.3A patent/EP4243824B1/en active Active
- 2021-11-12 CA CA3198246A patent/CA3198246A1/en active Pending
- 2021-11-12 US US18/036,719 patent/US20230338358A1/en active Pending
-
2023
- 2023-05-09 ZA ZA2023/05122A patent/ZA202305122B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4243824B1 (en) | 2025-12-24 |
| MX2023005563A (es) | 2023-09-11 |
| ES3061585T3 (en) | 2026-04-06 |
| WO2022101395A1 (en) | 2022-05-19 |
| ZA202305122B (en) | 2024-08-28 |
| CN116685353A (zh) | 2023-09-01 |
| CA3198246A1 (en) | 2022-05-19 |
| KR20230107269A (ko) | 2023-07-14 |
| EP4243824A1 (en) | 2023-09-20 |
| AU2021376885A1 (en) | 2023-06-08 |
| US20230338358A1 (en) | 2023-10-26 |
| JP2023549849A (ja) | 2023-11-29 |
| EP4243824C0 (en) | 2025-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4003327B1 (en) | Compounds for use in the treatment of paroxysmal nocturnal haemoglobinuria (pnh) | |
| EP4243824B1 (en) | Prophylaxis and treatment of angioedema | |
| Chapman et al. | Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers | |
| US20180161314A1 (en) | Methods for Treating Hyperuricemia and Related Diseases | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
| US20230404971A1 (en) | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid | |
| KR102766876B1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
| AU2016244263A1 (en) | Combination ALS therapy | |
| JP2020510675A (ja) | ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防 | |
| US11571408B2 (en) | Cancer treatment using docetaxel by controlling peak plasma levels | |
| JPH11500140A (ja) | アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物 | |
| JPH11507012A (ja) | 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療 | |
| HK40099091B (en) | Prophylaxis and treatment of angioedema | |
| HK40099091A (en) | Prophylaxis and treatment of angioedema | |
| US20240423961A1 (en) | 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones | |
| Esseku et al. | A randomized Phase I bioequivalence clinical trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers | |
| EP4663187A1 (en) | 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain | |
| CN113226374B (zh) | 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物 | |
| KR20240019265A (ko) | Mmp-12 억제제의 안전한 투여 | |
| KR19980702100A (ko) | 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제, 부작용-감소된 양의 알도스테론 길항제 및 이뇨제의 조합 치료요법 |